FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655174> ?p ?o ?g. }

• W4385655174 endingPage "e676299d" @default.
• W4385655174 startingPage "e676299d" @default.
• W4385655174 abstract "Topic: 12. Bone marrow failure syndromes incl. PNH - Clinical Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder associated with bone marrow failure and thrombosis. Pegcetacoplan, a targeted complement protein C3 therapy, is approved for the treatment of PNH in the European Union, the United Kingdom, and the United States. Aims: Exposure-response (E-R) relationships were investigated using hemoglobin (Hb) and lactate dehydrogenase (LDH) as clinical efficacy endpoints to inform the proposed clinical dose. Methods: A population E-R analysis was performed to describe responses of the biomarkers Hb and LDH to pegcetacoplan in patients with PNH using data from 5 clinical studies, including 2 phase 3 studies (PRINCE in patients naive to C5 inhibitors, PEGASUS in patients switched from eculizumab), both with pegcetacoplan 1080-mg subcutaneous (SC) twice-weekly dosing. Intrinsic (Asian race, age, body weight, baseline C3, creatinine clearance [CrCL], and sex) and extrinsic (pegcetacoplan exposure, eculizumab experience) factors were included in the model as prespecified covariates to quantify their impact on the E-R relationship. Simulations were performed to evaluate predicted Hb and LDH responses to pegcetacoplan 1080 mg SC dosed twice weekly or every 3 days. The E-R relationships for increased Hb and decreased LDH with increasing pegcetacoplan exposure were described with direct, sigmoidal maximal effect (Emax) models. Results: The maximum effect of pegcetacoplan was a 51.0% increase in Hb from a baseline of 8.74 g/dL. A pegcetacoplan concentration of 337 μg/mL achieved 50% of Emax (EC50) with a Hill coefficient of 4.66 describing the sigmoidicity of the relationship. The baseline LDH and LDH Emax were dependent on prior C5 inhibitor treatment while the LDH EC50 (187 μg/mL) and Hill coefficients (3.42) were consistent in both populations. The Emax was a 91.7% decrease from a baseline LDH of 1920 IU/L and a 20.0% decrease from a baseline LDH of 249 IU/L for C5 inhibitor-naive and experienced patients, respectively. The median (interquartile range [IQR]) steady-state pegcetacoplan serum concentration of 667 (551–782) μg/mL associated with 1080-mg twice-weekly dosing is expected to achieve at least 95% of Hb and LDH Emax in patients who are treatment-naive and in patients switching from C5 inhibitors. Baseline CrCL and sex affected Emax of Hb, but the magnitude of difference was not anticipated to be clinically relevant. Median (IQR) predicted Hb at steady-state for patients receiving pegcetacoplan 1080 mg twice weekly was 11.7 (10.5–13.3) g/dL. Median (IQR) predicted LDH at steady-state following pegcetacoplan 1080-mg twice-weekly dosing was 217 (170–292) U/L for complement inhibitor-naive patients and 192 (148–260) U/L for patients switching from eculizumab to pegcetacoplan, with 84.3% of naive patients and 96.7% of switch patients predicted to achieve LDH control (defined as <1.5 times the upper limit of normal). Asian race, age, body weight, and baseline C3 level were not found to have clinically or statistically meaningful effects on either Hb or LDH response to pegcetacoplan. Additionally, prior eculizumab treatment did not have an effect on Hb response. Sex and baseline CrCL did not have a meaningful effect on LDH response to pegcetacoplan. Summary/Conclusion: Relationships of Hb and LDH responses with pegcetacoplan exposure were well described by the models. Pegcetacoplan 1080 mg SC twice weekly dosing was supported by the models as effective in patients with PNH who are naive to complement inhibitors and in those switching from C5 inhibitors to pegcetacoplan. Keywords: Hemoglobin, Complement, Anemia, Paroxysmal nocturnal hemoglobinuria (PNH)" @default.
• W4385655174 created "2023-08-09" @default.
• W4385655174 creator A5027393041 @default.
• W4385655174 creator A5035978160 @default.
• W4385655174 creator A5046114886 @default.
• W4385655174 creator A5082920242 @default.
• W4385655174 creator A5087550018 @default.
• W4385655174 creator A5092611914 @default.
• W4385655174 date "2023-08-01" @default.
• W4385655174 modified "2023-09-27" @default.
• W4385655174 title "PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA" @default.
• W4385655174 doi "https://doi.org/10.1097/01.hs9.0000975016.67629.9d" @default.
• W4385655174 hasPublicationYear "2023" @default.
• W4385655174 type Work @default.
• W4385655174 citedByCount "0" @default.
• W4385655174 crossrefType "journal-article" @default.
• W4385655174 hasAuthorship W4385655174A5027393041 @default.
• W4385655174 hasAuthorship W4385655174A5035978160 @default.
• W4385655174 hasAuthorship W4385655174A5046114886 @default.
• W4385655174 hasAuthorship W4385655174A5082920242 @default.
• W4385655174 hasAuthorship W4385655174A5087550018 @default.
• W4385655174 hasAuthorship W4385655174A5092611914 @default.
• W4385655174 hasBestOaLocation W43856551741 @default.
• W4385655174 hasConcept C109159458 @default.
• W4385655174 hasConcept C111684460 @default.
• W4385655174 hasConcept C126322002 @default.
• W4385655174 hasConcept C159654299 @default.
• W4385655174 hasConcept C181199279 @default.
• W4385655174 hasConcept C203014093 @default.
• W4385655174 hasConcept C2777318727 @default.
• W4385655174 hasConcept C2777346216 @default.
• W4385655174 hasConcept C2777991916 @default.
• W4385655174 hasConcept C2778248108 @default.
• W4385655174 hasConcept C2778639011 @default.
• W4385655174 hasConcept C2780007613 @default.
• W4385655174 hasConcept C2780306776 @default.
• W4385655174 hasConcept C2780525284 @default.
• W4385655174 hasConcept C28328180 @default.
• W4385655174 hasConcept C2908647359 @default.
• W4385655174 hasConcept C54355233 @default.
• W4385655174 hasConcept C55493867 @default.
• W4385655174 hasConcept C71924100 @default.
• W4385655174 hasConcept C86803240 @default.
• W4385655174 hasConcept C90924648 @default.
• W4385655174 hasConcept C99454951 @default.
• W4385655174 hasConceptScore W4385655174C109159458 @default.
• W4385655174 hasConceptScore W4385655174C111684460 @default.
• W4385655174 hasConceptScore W4385655174C126322002 @default.
• W4385655174 hasConceptScore W4385655174C159654299 @default.
• W4385655174 hasConceptScore W4385655174C181199279 @default.
• W4385655174 hasConceptScore W4385655174C203014093 @default.
• W4385655174 hasConceptScore W4385655174C2777318727 @default.
• W4385655174 hasConceptScore W4385655174C2777346216 @default.
• W4385655174 hasConceptScore W4385655174C2777991916 @default.
• W4385655174 hasConceptScore W4385655174C2778248108 @default.
• W4385655174 hasConceptScore W4385655174C2778639011 @default.
• W4385655174 hasConceptScore W4385655174C2780007613 @default.
• W4385655174 hasConceptScore W4385655174C2780306776 @default.
• W4385655174 hasConceptScore W4385655174C2780525284 @default.
• W4385655174 hasConceptScore W4385655174C28328180 @default.
• W4385655174 hasConceptScore W4385655174C2908647359 @default.
• W4385655174 hasConceptScore W4385655174C54355233 @default.
• W4385655174 hasConceptScore W4385655174C55493867 @default.
• W4385655174 hasConceptScore W4385655174C71924100 @default.
• W4385655174 hasConceptScore W4385655174C86803240 @default.
• W4385655174 hasConceptScore W4385655174C90924648 @default.
• W4385655174 hasConceptScore W4385655174C99454951 @default.
• W4385655174 hasIssue "S3" @default.
• W4385655174 hasLocation W43856551741 @default.
• W4385655174 hasLocation W43856551742 @default.
• W4385655174 hasOpenAccess W4385655174 @default.
• W4385655174 hasPrimaryLocation W43856551741 @default.
• W4385655174 hasRelatedWork W142766978 @default.
• W4385655174 hasRelatedWork W1569661065 @default.
• W4385655174 hasRelatedWork W1958056281 @default.
• W4385655174 hasRelatedWork W2008673097 @default.
• W4385655174 hasRelatedWork W2049544798 @default.
• W4385655174 hasRelatedWork W2093098007 @default.
• W4385655174 hasRelatedWork W2465204721 @default.
• W4385655174 hasRelatedWork W2794410908 @default.
• W4385655174 hasRelatedWork W2956779257 @default.
• W4385655174 hasRelatedWork W4205997654 @default.
• W4385655174 hasVolume "7" @default.
• W4385655174 isParatext "false" @default.
• W4385655174 isRetracted "false" @default.
• W4385655174 workType "article" @default.